Jiangsu Jibeier Pharmaceutical (688566) Fundamentals 2026 — P/E 19.4x, Revenue Analysis | SniperIQ
Jiangsu Jibeier Pharmaceutical (688566) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.9B, trading at ¥24.40 on the SHH. This SniperIQ fundamentals page covers Jiangsu Jibeier Pharmaceutical's valuation (P/E 19.4x, P/B 2.0x), profitability (net margin 25.4%), revenue (¥965M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiangsu Jibeier Pharmaceutical's market cap?
Jiangsu Jibeier Pharmaceutical (688566) has a market capitalization of approximately ¥4.9B, trading at ¥24.40 on the SHH. Market cap moves with the live share price.
What is Jiangsu Jibeier Pharmaceutical's P/E ratio?
Jiangsu Jibeier Pharmaceutical's trailing twelve-month P/E ratio is 19.4x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiangsu Jibeier Pharmaceutical?
Jiangsu Jibeier Pharmaceutical runs a net profit margin of 25.4%, a gross margin of 85.2%, and an operating margin of 24.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiangsu Jibeier Pharmaceutical generate?
Jiangsu Jibeier Pharmaceutical reported revenue of ¥965M for fiscal year 2025, with net income of ¥259M and earnings per share (EPS) of 1.3. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiangsu Jibeier Pharmaceutical pay a dividend?
Jiangsu Jibeier Pharmaceutical offers a trailing dividend yield of about 2.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jiangsu Jibeier Pharmaceutical financially healthy?
Jiangsu Jibeier Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 9.35x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiangsu Jibeier Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangsu Jibeier Pharmaceutical (688566) the key facts are: market cap ¥4.9B, P/E 19.4x, revenue ¥965M, 52-week range 22.82-44.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiangsu Jibeier Pharmaceutical's full fundamentals live
Get Jiangsu Jibeier Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.